DOW JONES, A NEWS CORP COMPANY
News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services.
DOW JONES
  • Barron's
  • BigCharts
  • DJX
  • Dow Jones Newswires
  • Factiva
  • Financial News
  • Mansion Global
  • MarketWatch
  • Newsmart
  • NewsPlus
  • Private Markets
  • Risk & Compliance
  • WSJ.com
  • WSJ Pro
  • WSJ Conference
  • WSJ Video
NEWS CORP
  • Big Decisions
  • Business Spectator
  • Checkout51
  • Harper Collins
  • New York Post
  • PropTiger
  • REA
  • realtor.com
  • Storyful
  • The Australian
  • The Sun
  • The Times
ダウ平均 ▲
17533.51 0.19%
  S&P 500 ▲
2054.19 0.09%
  ナスダック ▲
4787.64 0.38%
  米10年債 ▲
1/32 yield 1.839%
  原油 ▲
47.72 -1.43%
  ユーロ/ドル ▲
1.1194 -0.29%
 
Subscribe Now Sign In
The Wall Street Journal
日本 (Japan)
  • U.S.
  • Asia
  • Europe
  • India
  • América Latina
  • Brasil
  • 中国 (China)
  • 日本 (Japan)
2016年5月23日
Sections
My Journal
  • ホーム
  • 経済
  • マーケット
  • ビジネス
  • テクノロジー
  • 国際
  • 国内
  • オピニオン・社説
  • ライフ
  • バロンズ
  • SHOW ALL SECTIONS HIDE ALL SECTIONS
    • 経済
      • 金融政策ウォッチ
      • Heard on the Street
    • マーケット
      • マーケットデータ
    • テクノロジー
      • ガジェットレビュー
    • 国際
      • 北米
      • 米大統領選特集
      • アジア・オセアニア
      • 欧州
      • 中東・アフリカ
      • China's World
      • China Real Time Report
    • 国内
      • 編集長インタビュー
    • オピニオン・社説
      • オピニオ ン
      • 社説
    • ライフ
      • キャリア
      • ヘルス
    • バロンズ
      • 日本市場
      • IT注目銘柄
      • インタビュー
      • コラム
    HIDE ALL SECTIONS
Sign In
  • ホーム
  • 経済
    • 金融政策ウォッチ
    • Heard on the Street
  • マーケット
    • マーケットデータ
  • ビジネス
  • テクノロジー
    • ガジェットレビュー
  • 国際
    • 北米
    • 米大統領選特集
    • アジア・オセアニア
    • 欧州
    • 中東・アフリカ
    • China's World
    • China Real Time Report
  • 国内
    • 編集長インタビュー
  • オピニオン・社説
    • オピニオ ン
    • 社説
  • ライフ
    • キャリア
    • ヘルス
  • バロンズ
    • 日本市場
    • IT注目銘柄
    • インタビュー
    • コラム
Search
Subscribe Sign In

Pfizer Inc. PFE (U.S.: NYSE)

View All companies
  • REAL TIME 10:07 AM EDT 05/23/16
  • $33.7885 USD
  • 0.0485 0.14%
  • Volume 1,619,476
  • Volume 1,619,476
  • 65 Day Avg Vol 45,592,407
  • 1 Day Range 33.68 - 33.85
  • 52 Week Range 28.25 - 36.46 (02/08/16 - 07/31/15)
  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • YTD
  • 1 Y
  • 3 Y
  • $
  • %
Advanced Charting Compare
  • Compare to Benchmark:
  • DJIA
  • S&P 500
  • GLOBAL DOW
  • NASDAQ
  • Health Care/Life Sciences
  • Compare to
  • Open 33.83
  • Prior Close 33.74 (05/20/16)
  • 1 Day
  • PFE 0.14%
  • DJIA 0.19%
  • S&P 500 0.09%
  • Health Care/Life Sciences 1.05%
  • Overview

News Pfizer Inc.PFE

    • 3 hours ago
    • Press Release
    CHAMPIX(R) (varenicline) European Union Label Updated to Include New Safety and Efficacy Data from the EAGLES Clinical Trial Following Endorsement from CHMP
    • Press Release
    • 05/21/16
    • MarketWatch.com
    How to lose a billion dollars: Beer heiress Frances Stroh’s journey to financial freedom
    • MarketWatch.com
    • 05/20/16
    • Press Release
    Pfizer Announces European Medicines Agency Acceptance for Review of Marketing Authorization Application for TRUMENBA(R) (Meningococcal Group B Vaccine)
    • Press Release
    • 05/20/16
    • Press Release
    On BizWireTV: Streaming Service Finds Television and Climate Change on the Radar
    • Press Release
    • 05/19/16
    • Press Release
    Hospira Launches LifeCare PCA(R) 7.0 Infusion System, First PCA Pump That Integrates with the Electronic Medical Record
    • Press Release
    • 05/19/16
    • Press Release
    Spark Therapeutics and Pfizer Announce Data from Initial Subjects in Hemophilia B Trial Demonstrating Consistent Therapeutic Levels of Factor IX Expression
    • Press Release
    • 05/18/16
    • Press Release
    Merck and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting
    • Press Release
    • 05/18/16
    • Press Release
    Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting
    • Press Release
    • 05/18/16
    • Press Release
    Pfizer to Showcase Diverse and Growing Oncology Portfolio at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
    • Press Release
    • 05/17/16
    • Press Release
    INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Anacor Pharmaceuticals, Inc. to Pfizer Inc. for $99.25 Per Share -- ANAC
    • Press Release
    • 05/17/16
    • Press Release
    Block & Leviton LLP Investigates Anacor Pharmaceuticals Inc., Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Pfizer Inc.
    • Press Release
    • 05/17/16
    • Press Release
    Kinder Morgan, Pfizer Inc., Lowes, Accenture, and Ulta Salon Cosmetics & Fragrance Inc. and more offer option-trading opportunities that offer returns of more than 20%
    • Press Release
    • 05/17/16
    • Press Release
    Global Survey Finds Disconnects Between Physicians and People Living With Rheumatoid Arthritis (RA)
    • Press Release
    • 05/16/16
    • Dow Jones Newswires
    Paulson & Co. Discloses Holdings as of Quarter-End
    • Dow Jones Newswires
    • 05/16/16
    • MarketWatch.com
    4 things to know about Pfizer’s $5.2 billion acquisition target, Anacor
    • MarketWatch.com
    • 05/16/16
    • The Wall Street Journal
    Biotech M&A: Pfizer Bets on Growth
    • The Wall Street Journal
    • 05/16/16
    • The Wall Street Journal
    Pfizer to Buy Anacor for $4.5 Billion
    • The Wall Street Journal
    • 05/16/16
    • Press Release
    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
    • Press Release
    • 05/16/16
    • Dow Jones Newswires
    U.S. Hot Stocks to Watch: Hot Stocks to Watch
    • Dow Jones Newswires
    • 05/16/16
    • Press Release
    ANACOR (ANAC) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of Anacor Pharmaceuticals, Inc.; Are Shareholders Getting a Fair Price?
    • Press Release
    • 05/16/16
    • MarketWatch.com
    Pfizer to buy Anacor for $4.5 billion
    • MarketWatch.com
    • 05/16/16
    • Press Release
    Pfizer Files 8K - Regulation FD >PFE
    • Press Release
    • 05/16/16
    • Dow Jones Newswires
    Pfizer to Buy Anacor for $4.5 Billion
    • Dow Jones Newswires
    • 05/16/16
    • Press Release
    Pfizer to Acquire Anacor
    • Press Release
    • 05/13/16
    • Dow Jones Newswires
    Pfizer Tightens Controls to Block Use of Its Drugs in Executions
    • Dow Jones Newswires
    • 05/13/16
    • The Wall Street Journal
    Pfizer Tightens Controls to Block Use of Its Drugs in Executions
    • The Wall Street Journal
    • 05/13/16
    • WSJ Blogs
    Third Point Takes Stake in Alphabet; Cuts Amgen and Allergan in First Quarter
    • WSJ Blogs
    • 05/13/16
    • Press Release
    Pfizer Presents Results from Two Phase 3 TRUMENBA(R) (Meningococcal Group B Vaccine) Studies at the European Society for Paediatric Infectious Diseases Meeting
    • Press Release
    • 05/12/16
    • WSJ Blogs
    Break Fee Bonanza as Deals Fail
    • WSJ Blogs
    • 05/11/16
    • Press Release
    Pfizer Awards More Than $1 Million in Metastatic Breast Cancer Research Funding Through Breast Cancer: A Story Half Told Initiative
    • Press Release
    • 05/10/16
    • MarketWatch.com
    6 favorite dividend stocks from a conservative money manager
    • MarketWatch.com
    • 05/10/16
    • The Wall Street Journal
    Markit’s Profit Falls on Higher Personnel Costs
    • The Wall Street Journal
    • 05/10/16
    • Barron's
    Three Big Pharma Stocks Headed Higher
    • Barron's
    • 05/07/16
    • Barron's
    They Said What?
    • Barron's
    • 05/04/16
    • WSJ Blogs
    Deals of the Day: MultiPlan Sale Looms, ICE Says No to LSE Bid
    • WSJ Blogs
    • 05/03/16
    • WSJ Blogs
    2016 Is Already a Record Year for Failed U.S. Deals
    • WSJ Blogs
    • 05/03/16
    • The Wall Street Journal
    Why Pfizer Is Loving the Weak Dollar
    • The Wall Street Journal
    • 05/03/16
    • Press Release
    InvestorsObserver releases covered-call reports for Gilead Sciences, Pfizer Inc., Valeant Pharmaceuticals, AIG and Oracle Corporation
    • Press Release
    • 05/03/16
    • Press Release
    InvestorsObserver releases covered-call reports for Gilead Sciences, Pfizer Inc., Valeant Pharmaceuticals, AIG and Oracle Corporation
    • Press Release
    • 05/03/16
    • WSJ Blogs
    Stocks to Watch: Mallinckrodt, Mylan, Pfizer, Sprint, Vivint Solar
    • WSJ Blogs
load more
Key Stock Data
?
P/E Ratio (TTM)
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Earnings Per Share (TTM)
A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization
Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
Shares Outstanding
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Public Float
The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
Dividend Yield
A company's dividend expressed as a percentage of its current stock price.

Key Stock Data

  • P/E Ratio (TTM)
    24.99 (05/23/16)
  • EPS (TTM)
    $1.35
  • Market Cap
    $204.63 B
  • Shares Outstanding
    6.19 B
  • Public Float
    6.19 B
  • Yield
    3.56% (05/23/16)
  • Latest Dividend
    $0.30 (06/01/16)
  • Ex-Dividend Date
    05/11/16
?
Shares Sold Short
The total number of shares of a security that have been sold short and not yet repurchased.
Change from Last
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Percent of Float
Total short positions relative to the number of shares available to trade.

Short Interest (04/29/16)

  • Shares Sold Short
    108.39 M
  • Change from Last
    -27.65%
  • Percent of Float
    1.75%
?
Money Flow Uptick/Downtick Ratio
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

  • Uptick/Downtick Trade Ratio
    0 2
    1.14
    Net Money Flow ($)
    689,449

    Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.

Advertisement

Competitors PFE

Company Change P/E (TTM)
AMGN

Amgen Inc.

+0.18% +0.27 15.88
AZN

AstraZeneca PLC ADR

+0.14% +0.04 25.38
GSK

GlaxoSmithKline PLC ADR

+0.19% +0.08 111.02
NVS

Novartis AG ADR

+2.74% +2.08 28.18
ABT

Abbott Laboratories

+0.04% +0.02 23.35
BMY

Bristol-Myers Squibb Co.

-0.85% -0.60 72.23
JNJ

Johnson & Johnson

-0.44% -0.49 20.43
LLY

Eli Lilly & Co.

-0.03% -0.02 34.77
MRK

Merck & Co. Inc.

-0.05% -0.03 33.85
MYL

Mylan N.V.

-0.43% -0.18 26.49
  • More information on PFE
  • Competitor Data Provided By: capital cube

Profile PFE

Pfizer, Inc. is a research-based, global biopharmaceutical company, which engages in the manufacture of vaccines and injectable biologic medicines. It operates through the following segments: Global Innovative Pharmaceutical, Global Vaccines, Oncology and Consumer Healthcare,...

235 East 42nd Street
New York New York 10017
United States

  • Email
  • Website
  • Map
  • Employees 97,900
    Sector Pharmaceuticals
  • Sales or Revenue 48.85 B
    Industry Health Care/Life Sciences
  • 1Y Sales Change -1.52%
    Fiscal Year Ends December 31 Download Reports
  • Ian C. Read Chairman & Chief Executive Officer
  • Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
  • Mikael Dolsten President-Worldwide Research & Development
  • Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
  • More

Research & Ratings Pfizer Inc.PFE

Per-Share Earnings, Actuals and Estimates

  • Quarterly
  • Annual
PFE will report FY 2016 earnings on 01/31/2017 PFE will report Q2 earnings on 07/26/2016
Actual Analyst Range Consensus
0.70 0.65 0.60 0.55 0.50
Actual 0.56
0.52
Actual 0.60
0.51
Actual 0.53
0.52
Actual 0.67
0.55
0.61
0.62
Q22015 Q3 Q4 Q12016 Q2 Q3
4 3 2 1 0
Actual 1.11
2.19
2.42
2.60
2.86
FY 2015 FY 2016 FY 2017 FY 2018
Q2 2016 Estimate Trends
Current: $0.61
1 month ago: $0.59
3 months ago: $0.59
Q3 2016 Estimate Trends
Current: $0.62
1 month ago: $0.61
3 months ago: $0.60
FY 2016 Estimate Trends
Current: $2.42
1 month ago: $2.30
3 months ago: $2.27
FY 2017 Estimate Trends
Current: $2.60
1 month ago: $2.52
3 months ago: $2.51
  • More

Financials Pfizer Inc.PFE

  • Quarterly
  • Annual

Net Income

0 800M 1.6B 2.4B 3.2B
Mar 2015 Jun 2015 Sep 2015 Dec 2015 Mar 2016
0 3B 6B 9B 12B
'11 '12 '13 '14 '15
Mar 2016 5-quarter trend
Net Income Growth +27.30%
Sales or Revenue 13.01 B
Sales or Revenue Growth +19.71%
EBITDA -
2015 5-year trend
Net Income Growth -23.53%
Sales or Revenue 48.85 B
Sales or Revenue Growth -1.52%
EBITDA +18.45 B
  • More
  • Overview

Notes & Data Providers

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.

Advertisement
  • Wall Street Journal
  • 日本 (Japan)
    • U.S.
    • Asia
    • Europe
    • India
    • América Latina
    • Brasil
    • 中国 (China)
    • 日本 (Japan)
  • Subscribe NowSign In

  • WSJ Membership Benefits
  • Download WSJ Apps
  • Customer Center
  • Legal Policies
  • Subscribe
  • Sign In
  • TOP«
  • Customer Service

  • Customer Center
  • Contact Us
  • About Houjin Subscribing
  • 学生割引購読
  • About Us
  • Ads

  • About Ads
  • Tools & Features

  • iPhone App
  • iPad App
  • Android App
  • Newsletter
  • About Japanese Blog Parts
  • More

  • Events
  • Jobs at WSJ
    • Facebook
    • Twitter
    • Google+
    • YouTube
    • Podcasts
    • Snapchat
    • GooglePlay
    • AppStore
    • Windows10
  • Dow Jones Products
  • Barron's
  • BigCharts
  • DJX
  • Dow Jones Newswires
  • Factiva
  • Financial News
  • Mansion Global
  • MarketWatch
  • Private Markets
  • realtor.com
  • Risk & Compliance
  • WSJ Conference
  • WSJ Pro Central Banking
  • WSJ Video
  • WSJ Wine
  • BallBall
  • Privacy Policy
  • Cookie Policy
  • Tokusyo
  • Data Policy
  • Subscriber Agreement & Terms of Use
  • Copyright ©2016 Dow Jones & Company, Inc. All Rights Reserved.